On January 30, 2020 Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) and RIKEN Innovation Co., Ltd. (HQ: Saitama, Japan; President and CEO: Yoshihiro Aburatani) reported that they have signed a partnership agreement to use the research results from National Research and Development Institute RIKEN (HQ: Saitama, Japan; President: Hiroshi Matsumoto) to jointly create new businesses and return benefits to society (Press release, Sysmex, JAN 30, 2020, View Source [SID1234553683]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through this agreement, the companies aim to apply advanced and broad-ranging research results from RIKEN, a comprehensive research institution for the natural sciences. The objective is to create high-value testing and diagnostic technologies to resolve global medical issues and contribute to the realization of personalized medicine.
The healthcare issues faced by individual countries have grown more diverse in recent years, due to aging populations and the expansion of preventive medicine in developed countries, and the establishment of healthcare infrastructures in emerging markets. With IT and other technological innovations making industries increasingly borderless, it is important to respond to increasingly diverse healthcare needs, proactively collaborate with companies and research institutions that go beyond their industry boundaries, and conduct R&D activities leading to efficient and effective innovation and the creation of new business opportunities.
Sysmex has established an open innovation lab at Technopark (Nishi-ku, Kobe) to pursue collaboration with researchers in Japan and overseas. The Company is pursuing numerous joint research projects at global R&D centers and through its network of Group companies, centering on the development of new diagnostic applications. In these ways, Sysmex aims to acquire unique diagnostic technologies through open innovation with medical and research institutions in Japan and overseas.
As a wholly owned subsidiary of RIKEN, RIKEN Innovation is tasked with promoting collaboration between industry and academia that will quickly return value to society based on RIKEN’s research results. As Japan’s key comprehensive research institution for the natural sciences, RIKEN is involved in a broad range of research fields. By promoting the joint creation of businesses, RIKEN Innovation will leverage research results from diverse researchers engaged in fundamental and applied research. As a result, RIKEN Innovation aims to work together on a variety of measures that will help resolve issues faced by companies and society.
Sysmex and RIKEN Innovation have entered into a partnership agreement in the aim of leveraging RIKEN’s cross-disciplinary research results and Sysmex’s R&D knowhow related to diagnostic technologies to create new diagnostic technologies and new businesses that can be rolled out globally.
Based on this partnership agreement, the two companies will collaborate in searching for needs with a view to creating new diagnostic technologies, outlining diagnostic technology development themes, and building an R&D structure. The companies will pursue open innovation aimed at creating new businesses.
Going forward, by providing diagnostic technologies created under this agreement, Sysmex, RIKEN Innovation and RIKEN aim to create treatment opportunities for patients with diseases that have no established diagnostic methods and contribute to medical economy through more efficient healthcare.